Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance

被引：43

作者：

Kao, Ting-Wan ^{[1
,2
]}

Bai, Geng-Hao ^{[3
]}

Wang, Tian-Li ^{[4
,5
,6
]}

Shih, Ie-Ming ^{[4
,5
,6
]}

Chuang, Chi-Mu ^{[7
,8
,9
]}

Lo, Chun-Liang ^{[10
,11
]}

Tsai, Meng-Chen ^{[12
]}

Chiu, Li-Yun ^{[13
]}

Lin, Chu-Chien ^{[1
,14
]}

Shen, Yao-An ^{[1
,2
,15
]}

机构：

[1] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei 110301, Taiwan

[2] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 110301, Taiwan

[3] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Taipei City 100225, Taiwan

[4] Johns Hopkins Med Inst, Dept Pathol, 1550 Orleans St Room 306, CRB221231, Baltimore, MD USA

[5] Johns Hopkins Med Inst, Dept Oncol & Gynecol & Obstet, 1550 Orleans St Room 306, CRB221231, Baltimore, MD USA

[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA

[7] Natl Yang Ming Chiao Tung Univ, Fac Med, Sch Med, Taipei 112304, Taiwan

[8] Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei 112201, Taiwan

[9] Natl Taipei Univ Nursing & Hlth Sci, Dept Midwifery & Women Hlth Care, Taipei 112303, Taiwan

[10] Natl Yang Ming Chiao Tung Univ, Dept Biomed Engn, Taipei 112304, Taiwan

[11] Natl Yang Ming Chiao Tung Univ, Med Device Innovat & Translat Ctr, Taipei 112304, Taiwan

[12] Taipei Med Univ Hosp, Dept Gen Med, Taipei 110301, Taiwan

[13] Mackay Mem Hosp, Dept Gen Med, Taipei 104217, Taiwan

[14] Taipei Med Univ, Coll Med, Sch Med, Taipei City 110301, Taiwan

[15] Taipei Med Univ, Coll Med, Program Med, Taipei 110301, Taiwan

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期

关键词：

Hypoxia; HIF-1; HIF-2; Chemotherapy; Target therapy; Radiotherapy; Immunotherapy; Metabolic therapy; Therapeutic resistance; Combination therapy; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE-FACTOR; HEPATOCELLULAR-CARCINOMA; VEGF EXPRESSION; ANTITUMOR IMMUNITY; TUMOR OXYGENATION; DRUG-RESISTANCE; UP-REGULATION; LUNG-CANCER;

D O I：

10.1186/s13046-023-02724-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are established cancer treatment modalities that are widely used due to their demonstrated efficacy against tumors and favorable safety profiles or tolerability. Nevertheless, treatment resistance continues to be one of the most pressing unsolved conundrums in cancer treatment. Hypoxia-inducible factors (HIFs) are a family of transcription factors that regulate cellular responses to hypoxia by activating genes involved in various adaptations, including erythropoiesis, glucose metabolism, angiogenesis, cell proliferation, and apoptosis. Despite this critical function, overexpression of HIFs has been observed in numerous cancers, leading to resistance to therapy and disease progression. In recent years, much effort has been poured into developing innovative cancer treatments that target the HIF pathway. Combining HIF inhibitors with current cancer therapies to increase anti-tumor activity and diminish treatment resistance is one strategy for combating therapeutic resistance. This review focuses on how HIF inhibitors could be applied in conjunction with current cancer treatments, including those now being evaluated in clinical trials, to usher in a new era of cancer therapy.

引用

页数：35

共 168 条

[1] Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy [J].

Abdel-Wahab, Ali F. ;

Mahmoud, Waheed ;

Al-Harizy, Randa M. .

PHARMACOLOGICAL RESEARCH, 2019, 150

[2] Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice [J].

Ahern, Elizabeth ;

Harjunpaa, Heidi ;

Barkauskas, Deborah ;

Allen, Stacey ;

Takeda, Kazuyoshi ;

Yagita, Hideo ;

Wyld, David ;

Dougall, William C. ;

Teng, Michele W. L. ;

Smyth, Mark J. .

CLINICAL CANCER RESEARCH, 2017, 23 (19) :5789-5801

[3] The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy [J].

Albadari, Najah ;

Deng, Shanshan ;

Li, Wei .

EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (07) :667-682

[4] Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer [J].

Bao, Macus Hao-Ran ;

Wong, Carmen Chak-Lui .

CELLS, 2021, 10 (07)

[5] A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis [J].

Bao, Yi ;

Wang, Zhixiang ;

Liu, Bing ;

Lu, Xin ;

Xiong, Ying ;

Shi, Jiazi ;

Li, Peng ;

Chen, Junming ;

Zhang, Zongqin ;

Chen, Ming ;

Wang, Linhui ;

Wu, Zhenjie .

ONCOGENE, 2019, 38 (06) :881-895

[6] Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy [J].

Baran, Natalia ;

Konopleva, Marina .

CLINICAL CANCER RESEARCH, 2017, 23 (10) :2382-2390

[7] The hypoxia-inducible miR-429 regulates hypoxia-inducible factor-1α expression in human endothelial cells through a negative feedback loop [J].

Bartoszewska, Sylwia ;

Kochan, Kinga ;

Piotrowski, Arkadiusz ;

Kamysz, Wojciech ;

Ochocka, Renata J. ;

Collawn, James F. ;

Bartoszewski, Rafal .

FASEB JOURNAL, 2015, 29 (04) :1467-1479

[8] Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms [J].

Baumeister, Julian ;

Chatain, Nicolas ;

Hubrich, Annika ;

Maie, Tiago ;

Costa, Ivan G. ;

Denecke, Bernd ;

Han, Lijuan ;

Kuestermann, Caroline ;

Sontag, Stephanie ;

Sere, Kristin ;

Strathmann, Klaus ;

Zenke, Martin ;

Schuppert, Andreas ;

Bruemmendorf, Tim H. ;

Kranc, Kamil R. ;

Koschmieder, Steffen ;

Gezer, Deniz .

LEUKEMIA, 2020, 34 (04) :1062-1074

[9] Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies [J].

Bottsford-Miller, Justin N. ;

Coleman, Robert L. ;

Sood, Anil K. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :4026-4034

[10]

Burroughs SK, 2013, FUTURE MED CHEM, V5, P553, DOI [10.4155/FMC.13.17, 10.4155/fmc.13.17]

← 1 2 3 4 5 6 7 8 9 10 →